- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:26 | Why researchers may have found the biological culprit behind Angelman syndrome | ||
| 11:26 | Ascletis' challenger to Lilly's Foundayo hits goals in phase 2 diabetes trial | ||
| Mi | Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3 | ||
| Mi | FDA's rare disease framework aims to 'stand the test of time' | ||
| Mi | 'The patient need is enormous': Syntax programs stem cells into pancreatic beta cells in 4 days | ||
| Mi | Biogen CEO tells analysts he's focused on early-stage R&D as 'we were not very good with that' | ||
| Mi | Lilly's retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown | ||
| Mi | As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out the gate | ||
| Mi | GSK predicts 'some limited impact' to UK roles as restructuring rolls on | ||
| Mi | Astellas makes $1.3B bet on Audax's preclinical push to reverse decades of IL-12 woes | ||
| Mi | The 2026 Biotech Graveyard | ||
| Di | From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama | ||
| Di | Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy | ||
| Di | Parkinson's-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs | ||
| Di | Corxel claims oral obesity drug is in the 'right lane' as biotech plans SPAC route to Nasdaq | ||
| Di | Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail | ||
| Di | GSK's B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial | ||
| Di | BMS joins 3-year partnership to boost participation in cancer trials | ||
| Mo | Boehringer, Microsoft team up to explore digital patient twins for clinical trials | ||
| Mo | Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing | ||
| Mo | Windward Bio | ||
| Mo | ESMO: Why Incyte sees itself 'neck and neck' with RevMed in KRAS G12D pancreatic cancer race | ||
| Mo | Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing | ||
| Mo | ESMO: Genmab posts phase 3 win for Elahere rival, ahead of 'very interesting' data from Merus buyout | ||
| Mo | BioNTech sees 'limited' benefit to ADC after phase 3 reveals modest efficacy, ILD cases |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.